TrialJournal of the European Academy of Dermatology and Venereology : JEADV2017

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).

K Reich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.